SHH and pilomatrixoma: Category 2• Complex pharmacology underlying Shh and catenin signaling and the proposed mode of action resulting in pilomatricoma raised concerns of over- or under-estimating human risk• Potential off-target effects• Potential hormonal effects (increase in FSH and LH)• Discussion on safety margins not sufficient• Experience with drug class insufficient to aid prediction for the compound